- Previous Close
20.85 - Open
20.80 - Bid 21.15 x --
- Ask 21.30 x --
- Day's Range
20.80 - 21.30 - 52 Week Range
19.20 - 33.60 - Volume
57,632 - Avg. Volume
231,525 - Market Cap (intraday)
2.174B - Beta (5Y Monthly) 0.81
- PE Ratio (TTM)
-- - EPS (TTM)
-2.88 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. The company's products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the PCR amplification, hybridization, and detection steps of molecular testing; and the BioCode 2500 analyzer, a system that reads barcoded magnetic beads (BMB) and displays the barcode and fluorescence intensity for each BMB. It develops assays, such as BioCode SARS-CoV-2 Assay, a nucleic acid assay for the detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs; and CoV-2 Flu Assay for detection of RNA and various Influenza, as well as offers gastrointestinal and respiratory pathogen panel related products. In addition, the company provides general purpose reagents and manufactures 28 fungal analyte specific reagents. Further, it offers barcoded bead related accessories. Applied BioCode Corporation is based in Santa Fe Springs, California.
www.apbiocode.comRecent News: 6598.TW
View MorePerformance Overview: 6598.TW
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6598.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6598.TW
View MoreValuation Measures
Market Cap
2.17B
Enterprise Value
1.34B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.59
Price/Book (mrq)
2.47
Enterprise Value/Revenue
3.89
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-76.02%
Return on Assets (ttm)
-15.73%
Return on Equity (ttm)
-33.88%
Revenue (ttm)
343.07M
Net Income Avi to Common (ttm)
-260.81M
Diluted EPS (ttm)
-2.88
Balance Sheet and Cash Flow
Total Cash (mrq)
857.49M
Total Debt/Equity (mrq)
2.22%
Levered Free Cash Flow (ttm)
-109.98M